Year All 2026 2025 November 4, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 30, 2026 Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update October 22, 2026 Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy October 5, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 29, 2026 Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis September 8, 2026 Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis September 4, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 1, 2026 Vor Bio To Participate in Upcoming September Conferences August 11, 2026 Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update August 3, 2026 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 22, 2026 Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
September 29, 2026 Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
September 8, 2026 Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis